Clinical trial registry record

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 6, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07317934
Last registry update
August 6, 2026
Status
Recruiting
Phase
Phase 3
Sponsor
Innostellar Biotherapeutics Co.,Ltd
Enrollment
388
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
388
Population
ALL · 50 Years to 80 Years
Duration
2026-01-14 to 2032-06-04
Intervention
LX102; Aflibercept
Comparator
Aflibercept
Outcomes measured
Mean change from D0 in BCVA based on an average at weeks 48 and 56. — Week 56; Proportion of participants with improved BCVA — Week 56 and week 104; Proportion of participants with worsened BCVA — Week 56 and week 104; Mean change from D0 in CST based on an average at weeks 48 and 56 — Week 56; Proportion of participants without SRF/IRF on OCT at week 56 — Week 56; Proportion of participants who were supplemental anti-VEGF injection-free — Through 56 weeks; Proportion of participants who received 1 or 2 aflibercept injections — Through 56 weeks; Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56 — Through 56 weeks; Incidence of ocular and nonocular AEs and SAEs — 56 weeks; Immunogenicity characteristics of LX102 — 56 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON